Regulatory Headwinds Cloud Hims & Hers' Growth Trajectory

Digital health firm Hims & Hers posted strong 2025 results but shares fell as its 2026 guidance, tempered by regulatory scrutiny on weight-loss products, missed some estimates.

Digital health provider Hims & Hers delivered a powerful performance for 2025, yet investor sentiment turned cautious as the company's forward guidance highlighted looming regulatory challenges. The market's focus has shifted from past successes to potential pressures on a key product segment in the coming year.

A Strong Foundation: 2025 Performance Highlights

The company closed its 2025 fiscal year with remarkable momentum. Annual revenue surged to $2.35 billion, representing a substantial 59% increase compared to the previous year. The final quarter continued this trend, generating $617.8 million in sales for a solid year-over-year growth rate of 28%.

A critical driver behind these figures is the expanding subscriber base. By year-end, Hims & Hers reported over 2.5 million active subscribers. Profitability also exceeded expectations, with fourth-quarter earnings per share coming in at $0.08, surpassing the consensus forecast among market analysts.

The 2026 Outlook: Guidance Tempered by Regulatory Scrutiny

Despite the robust 2025 results, the company's projections for the new fiscal year captured the market's immediate attention. For the first quarter of 2026, management anticipates revenue in the range of $600 million to $625 million, a figure that reportedly fell short of some analyst estimates.

Company leadership cited anticipated burdens from regulatory changes as the primary reason for this conservative outlook. These changes are expected to impact the distribution of personalized weight reduction products. This specific area has already been under increased observation, as the firm's weight management offerings have attracted greater regulatory attention recently. Consequently, the strategy surrounding compounded medications is facing heightened examination.

For the full 2026 year, Hims & Hers has provided a revenue forecast of between $2.7 billion and $2.9 billion. Following the release of both the earnings and the guidance, the company's shares declined in after-hours trading.

Strategic Moves: Diversification and Executive Compensation

In parallel, the business is actively working to reduce its reliance on any single service line and to broaden its international footprint. This strategy aligns with the recently announced agreement to acquire Eucalyptus, an Australian digital health platform.

In a separate development on February 25, it was disclosed that CEO Andrew Dudum was granted 794,002 performance-based Restricted Stock Units. This award followed confirmation from the compensation committee that the necessary performance targets had been met as of February 23.

The current share price reflects persistent market uncertainty. The stock closed yesterday's session at €13.40, trading only marginally above its 52-week low of €13.12.

Moving forward, investor attention will likely center on two critical factors: whether the impending regulatory adjustments will constrain the weight-loss segment more severely than currently projected, and if the planned acquisition of Eucalyptus can provide additional support for the 2026 growth narrative.